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SHORT COMMUNICATION
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The discovery of the amphibian skin tetradecapeptide
bombesin led to the identification of several mammalian
bombesin-like neuroendocrine peptides such as gastrin-
releasing peptides (GRP'-27 and GRP"8-27) and neuromedin
B. GRP and neuromedin B are products of two distinct genes
(Krane et al., 1988). Bombesin and its homologues stimulate
gastric acid secretion and cause release of various peptide
hormones (Dockray, 1987). Bombesin is also mitogenic, caus-
ing gastrin cell hyperplasia in rats (Lezoche et al., 1981) and
stimulating proliferation of 3T3 murine fibroblasts (Rozen-
gurt & Sinnett-Smith, 1980) and normal human bronchial
epithelial cells (Willey et al., 1984) in vitro. Bombesin-like
peptides may act as autocrine mitogens for small cell car-
cinoma of the lung (SCCL); SCCL lines secrete bombesin-
like immunoreactivity (BLI) and are stimulated to proliferate
by exogenous bombesin (Cuttita et al., 1985). Some SCCL
lines are, however, insensitive to exogenous bombesin and do
not express detectable GRP receptors (Kado-Fong &
Malfroy, 1989).
BLI has been found in rat mammary tumours (Gaudino et
al., 1984) and in a small proportion of human breast cancer
and breast carcinoid specimens (Foster & Tan, 1984; McKil-
lop et al., 1988; Nesland et al., 1985) but is undetectable in
normal breast tissue (Bostwick & Bensch, 1985). Recently, it
was shown that both bombesin and GRP stimulate inositol
phospholipid hydrolysis and Ca2" efflux in MCF-7 and T47D
human breast cancer cells suggesting a role in mitogenic
signalling (Patel & Schrey, 1990). BLI has been detected in
MCF-7 and BT-20 breast cancer cell pellets (Weber et al.,
1989). This suggests that a BLI-autocrine stimulatory loop
may operate in some breast cancer cell lines such as is the
case for SCCL cells. In the light of these observations we
have investigated the effects of bombesin on the proliferation
of breast cancer cells in culture. The cell lines examined were
oestrogen-dependent (MCF-7), oestrogen-responsive (ZR-75-1,
T47D) (Dickson & Lippman, 1986), and oestrogen-
independent (MDA-MB-436) (Clarke et al., 1983).
ZR-75-1, T47D and MDA-MB-436 human breast cancer
cells were obtained from the European Collection of Animal
Cell Cultures (Porton Down, UK), MCF-7 cells (originally
from Dr M.E. Lippman, Georgetown, USA) were a gift from
Dr C.R. Green, Liverpool University. All tissue culture
media and foetal calf serum (FCS) were obtained from Flow
Labs, Irvine, Scotland, UK. The same reserved batch of FCS
was used throughout this investigation and all cells were
routinely passaged in the presence of phenol red. ZR-75-1
cells were cultured in RPMI 1640 medium containing 5%
FCS; MCF-7 in Eagle's minimal essential medium (MEM)
with 5% FCS; T47D cells in DMEM with 10% FCS; and
MDA-MB-436 cells in Liebowitz-15 medium with 10% FCS.
Bombesin (Bachem, Bubendorf, Switzerland) stock solu-
tions, made up in Earle's balanced salts solution containing
0.1% bovine serum albumin, were gassed with nitrogen to
prevent oxidation and were stored frozen in liquid nitrogen.
Heat- and charcoal-treated foetal calf serum (DCC-FCS) was
prepared by heating 100 ml of FCS, 10 g acid-washed Norit-
A activated charcoal and 1 g Dextran T40 at 53'C for 1 h
(charcoal and dextran previously stirred at 4'C overnight).
The suspension was centrifuged and then filtered through a
0.45 iLm membrane filter and finally filter-sterilised through a
0.22 pm membrane filter.
To study effects of the peptides on proliferation, cells were
inoculated into 24-well cluster plates (Costar, Northumbria
Biologicals, UK) at 1 x 104 (MDA-MB-436) or 4 x 104 (ZR-
75-1, T47D, MCF-7) cells per well and incubated at 37'C in
a humidified atmosphere containing 5% CO2. After 24 h,
plating efficiency was determined in 8 replicate wells by
electronic particle counting (Coulter counter model ZBI) of
trypsinised cells. Medium was removed from the remaining
wells and replaced either with medium containing 5% or
10% serum or with the same medium containing peptide, as
indicated. Cells from replicate wells were detached by treat-
ment with trypsin and counted at the times indicated; experi-
mental and control media were either unchanged during the
course of the experiment or were replaced on days 3 and 6 of
incubation. In serum-free conditions, 0.1% bovine serum
albumin replaced the serum component. All growth studies
were confirmed in at least three independent determinations.
Bombesin did not stimulate cell proliferation of any of the
lines in the presence of untreated FCS. The growth of ZR-
75-1 and T47D cells, however, was significantly and
consistently stimulated above control in the presence of
DCC-FCS (Figures 1 and 2). There were slight interexperi-
mental variations in the effective dose-response ranges for
each cell line but, under the culture conditions described,
significant stimulation of cell division was always found with
bombesin in the picomolar range.
Bombesin stimulates proliferation of ZR-75-1 cells grown
in the presence of 5% DCC-FCS, producing significant and
increasing elevations above control from day 3 to day 9 of
incubation (Figure la). Figure lb shows a typical dose-
response relationship of ZR-75-1 cells to added bombesin. In
this experiment 10-11 M-10-8 M bombesin caused >100%
increases in final cell numbers compared with control, while
10-7 M bombesin had no effect.
The growth response of T47D cells to bombesin was less
than that of the ZR-75-1 cells, and the mitogenic effect did
not persist beyond day 6. Figure 2 shows that continuous
exposure to 1-13M -1O-" M bombesin resulted in >50%
elevation of final cell numbers above control by day 6 of
incubation; in this experiment 1010 M bombesin had no
additional effect. Bombesin at <1013 M or >10-loM had
no effect on cell proliferation (not shown).
It was found that ZR-75-1 cells were maximally stimulated
by bombesin when medium changes were made on days 3
and 6 of incubation; less stimulation being produced when
medium was left unchanged. In contrast, T47D cells were
stimulated only when the dose of bombesin was left
unchanged for the course of the experiment.
MCF-7 cells did not respond to bombesin in either FCS or
DCC-FCS, when grown in phenol red-containing MEM.
Bombesin did stimulate proliferation of MCF-7 cells during
complete oestrogen withdrawal; that is, when grown in
phenol red-free MEM, containing DCC-FCS (Figure 3). This
effect was only produced in passages 5-13 following phenol
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red-withdrawal, earlier and later passages being unaffected by
bombesin. As with ZR-75-1 cells the effect of bombesin was
independent of medium changes.
In serum-free conditions ZR-75-1, T47D and MCF-7 cells
did not divide and addition of bombesin had no effect.
MDA-MB-436 cells divide slowly in serum-free conditions
and addition of bombesin stimulated their proliferation
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(Figure 4a), but bombesin had no effect on MDA-MB-436
cells in the presence of serum (Figure 4b).
Bombesin-like immunoreactivity in the foetal calf serum
was assayed by radioimmunoassay (RIA), as previously de-
scribed (Shaw et al., 1987). Serum samples (5 ml) were either
extracted with 10 volumes of ethanol/0.7 MHCl (3:1 vol./
vol.) by shaking overnight at 4°C, followed by centrifugation;
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Figure 3 Dose-response of phenol red-withdrawn MCF-7 cells
to bombesin in the presence of 5% DCC-FCS. Control and
experimental media were changed on days 3 and 6. Results are
mean cell number on day 9 ± s.d. (bars) of four wells. Significant
differences between treatment and control are indicated
(*P<0.05, **P<0.01, Student's t-test).
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5- Figure 1 a Effect of 0.1 nm Bombesin on ZR-75-1 cell prolifera-
tion and b, dose-response of ZR-75-1 cells to bombesin on day 9
of incubation in the presence of 5% DCC-FCS. Control and
experimental were media changed on days 3 and 6. 0, control;
0, treatment. Results are mean cell number ± s.d. (bars) of four
significant differences between treatment and control are
indicated (*P <0.05, **P <0.01, Student's t-test).
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Figure 2 Dose-response of T47D cells to bombesin in the
presence of 10% DCC-FCS. Control and experimental media
were unchanged. Results are mean cell number on day 6 ± s.d.
(bars) of four wells. Significant differences between treatment and
control are indicated (*P<0.05, **P<0.01, Student's t-test).
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Figure 4 Dose-response of MDA-MB-436 cells to bombesin a,
in serum-free conditions, or b, in the presence of 10% DCC-FCS.
Control and experimental media were changed on days 3 and 6.
Results are mean cell number on day 9 ± s.d. (bars) of four
wells. Significant differences between treatment and control are
indicated (*P <0.05, **P <0.01, Student's t-test).
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or the samples were separately passed four times through a
Sep-pak C-18 cartridge (Waters, UK), followed by washing
with 5 ml of 0.1% trifluoroacetic acid and elution with 3 ml
acetonitrile. The acid/ethanol supernatants were evaporated
to dryness in vacuo and the C-18 cartridge eluants were
lyophilised. Both were redissolved in assay buffer (40 mM
sodium phosphate buffer, pH 7.2, containing 140 mM NaCI
and 0.2% w/v bovine serum albumin (Sigma, RIA grade).
The antiserum was raised in rabbit against porcine GRP and
showed full molar cross-reactivity with both bombesin and
GRP18-27; hot ligand was mono-iodinated ['251]-Tyr4-
bombesin in the reduced form; cold competing ligand was
bombesin. The antibody had low cross-reactivity with the
oxidised form of bombesin (10%, unpublished data). The
lower limit of detection for acid/ethanol extraction was
3.2 pg ml' and for C-18 cartridge elution was 0.12 pg ml'.
Bombesin-like immunoreactivity of the FCS and DCC-
FCS was assayed in both acidified ethanol extracts and in
eluants form Sep-pak C-18 cartridges. The latter method
gives better recovery than the former, but both methods
indicate that heat- and dextran-coated charcoal treatment of
FCS results in greatly reduced levels of bombesin-like pep-
tides (Table I).
This report shows that bombesin stimulates the prolifera-
tion of four human breast cancer cell lines in culture. In the
case of ZR-75-1-cells the mammalian bombesin homologue
GRP'8-27 (neuromedin C) similarly stimulates proliferation
(Donnelly et al., 1990). The cell lines display a range of
responsiveness to bombesin and require distinct cultural con-
ditions for the mitogenic effect to be manifest.
Bombesin produces no stimulation of growth in the
presence of untreated FCS, but does stimulate growth of
ZR-75-1, T47D and oestrogen-withdrawn MCF-7 cells, when
grown in the presence of DCC-FCS. This may be due, in
part, to the reduced BLI content of DCC-FCS which allows
exogenous bombesin to exert additional stimulation. How-
ever, the concentration of BLI in DCC-FCS-containing media
(0.5-1 x 10-2M) would be expected to produce maximal
stimulation of T47D cells and thus prevent further stimula-
tion by additional bombesin. The BLI species in FCS have
not yet been characterised and it is possible that they are not
equipotent with bombesin. The concentration of BLI in FCS-
containing media (1-2 x 10-12 M) is below the maximum
effective dose for MCF-7 and MDA-MB-436 cells and it
would be expected that exogenous bombesin would produce
additional stimulation in the presence of FCS. In the
presence of FCS, however, the cells are probably dividing at
close to their maximum rate. Activated charcoal reduces
17p-oestradiol content of serum (Clarke et al., 1983) and is
used in RIA to remove free polypeptides from solution. It is
possible, therefore, that bombesin may substitute for
unrelated growth factors which are removed by heat and
charcoal treatment.
Table I Bombesin-like immunoreactivity in foetal calf serum
FCS (pgml-') DCC-FCS (pgml-')
Acidified ethanol 14 <3.2
extraction
Adsorption/elution 250 15
from C-18 cartridge
The oestrogen-responsive cell lines (ZR-75-1 and T47D,
Figures 1 and 2) are stimulated by bombesin in the presence
of phenol red, which is an oestrogen (Katzenellenbogen et
al., 1986). The oestrogen-dependent line, MCF-7, only re-
sponds to bombesin in early passages following complete
oestrogen-withdrawal (Figure 3). In this case, bombesin,
probably substitutes for oestrogen and phenol red. The
oestrogen-independent line, MDA-MB-436, does not respond
to bombesin except in the absence of serum (Figure 4), which
may imply that these cells are fully stimulated by factors
present in both FCS and DCC-FCS and that bombesin is
able to partially replace this requirement in serum-free condi-
tions. It is not yet understood why different culture condi-
tions are required for bombesin effects in the different cell
lines but frequency of medium changes, for example, has
been shown to determine the response of MDA-MB-436 cells
to epidermal growth factor (Nelson et al., 1989).
It may be that autocrine BLI production and/or expression
of GRP receptors is modulated by culture conditions and
this, in turn, modulates response to exogenous bombesin.
This possibility is currently being investigated. In the case of
the MCF-7 line, Weber et al. (1989) detected BLI in cell
pellets, whereas Carney et al. (1985) found no BLI in pellets
of five breast cancer cell lines, including MCF-7, T47D and
ZR-75-1. Preliminary results from this laboratory confirm
that MCF-7 cell pellets are negative for BLI, regardless of
whether grown in the presence or absence of phenol red
(unpublished observation).
The extent to which bombesin-like peptides are involved in
breast cancer development and growth is not clear at present.
The infrequent finding of BLI in malignant breast specimens
(Foster & Tan, 1984; McKillop et al., 1988; Nesland et al.,
1985; Bostwick & Bensch, 1985) suggests that a role as an
autocrine mitogen may be rare in breast cancer. It is possible,
however, that breast cancer is stimulated, due to an inappro-
priate response to circulating bombesin-like peptides. The
upper limit of normal for BLI in human plasma is 80 pM,
higher levels being found in some cancer patients (Sorensen
et al., 1982).
This work was supported by the Ulster Cancer Foundation and by
Action Cancer, Northern Ireland.
References
BOSTWICK, D.G. & BENSCH, K.G. (1985). Gastrin releasing peptide
in human neuroendocrine tumours. J. Pathol., 147, 237.
CARNEY, D.N., GAZDAR, A.F., BEPLER, G. & 5 others (1985). Estab-
lishment and identification of small cell lung cancer cell lines
having classic and variant features. Cancer Res., 45, 2913.
CLARKE, R., VAN DEN BERG, H.W., KENNEDY, D.G. & MURPHY,
R.F. (1983). Reduction of the anti-metabolic and anti-
proliferative effects ofmethotrexate by 17B-oestradiol in a human
breast cancer cell line, MDA-MB-436. Eur. J. Cancer Clin.
Oncol., 19, 19.
CUTTITA, F., CARNEY, D.N., MULSHINE, J. & 4 others (1985).
Bombesin-like peptides can function as autocrine growth factors
in human small cell carcinoma of the lung. Nature, 316, 823.
DICKSON, R.B. & LIPPMAN, M.E. (1986). Hormonal control of
human breast cancer cell lines. Cancer Surveys, 5, 617.
DOCKRAY, G.J. (1987). In Physiology of the Gastrointestinal Tract,
Johnson, L.R. (ed.), Vol. 1, pp. 41-66. Raven Press: New York.
DONNELLY, M., NELSON, J., WALKER, B., GRAY, J. & MURPHY,
R.F. (1990). The mitogenic activity of GRP'8-27 analogues on the
ZR-75-1 human breast cancer cell line. Biochem. Soc. Trans., 18,
354.
FOSTER, C.S. & TAN, K.S. (1984). Paracrine differentiation in human
primary breast carcinomas. Regul. Pept., 9, 329.
GAUDINO, G., DEBARTOLI, M. & LAZARUS, L.H. (1984). A
bombesin-related peptide in experimental mammary tumours in
rats. Ann. NY Acad. Sci., 464, 450.
KADO-FONG, H. & MALFROY, B. (1989). Effects of bombesin on
human small cell lung cancer cells: evidence for a subset of
bombesin non-responsive cell lines. J. Cell Biochem., 40, 431.
KATZENELLENBOGEN, B.S., BERTHOIS, Y., SHEEN, Y.Y. KENDRA,
K. & KATZENELLENBOGEN, J.A. (1986). Phenol red in tissue
culture media is a weak oestrogen. Anticancer Res., 6, 396.936 J. NELSON et al.
KRANE, I.M., NAYLOR, S.L., HELIN-DAVIS, D., CHIN,, W.W. &
SPINDEL, E.R. (1988). Molecular cloning of cDNAs encoding the
human bombesin-like peptide neuromedin B. Chromosomal
localization and comparison to cDNAs encoding its amphibian
homologue ranatensin. J. Biol. Chem., 263, 13317.
LEZOCHE, E., BASSO, N. & SPERANZA, V. (1981). In Gut Hormones
Bloom, S.R. & Polak, J.M. (eds) pp. 419-424. Churchill-
Livingstone: Edinburgh, Scotland.
MCKILLOP, J.M., CARRAGHER, A., JOHNSON, C.F., MURPHY, R.F. &
BUCHANAN, K.D. (1988). Identification of GRP in a small
population of human breast carcinomas. Regul. Pept., 22, 420.
NELSON, J., MCGIVERN, M., WALKER, B., BAILIE, J.R. & MURPHY,
R.F. (1989). Growth-inhibitory and growth-stimulatory effects of
epidermal growth factor on human breast cancer cell line, MDA-
MB-436: dependence on culture conditions. Eur. J. Cancer Clin.
Oncol., 25, 1851.
NESLAND, J.M., MEMOLI, V.A., HOLM, R., GOULD, V.E. & JOHAN-
NESSEN, J.V. (1985). Breast carcinomas with neuroendocrine
differentiation. Ultrastruct. Pathol., 8, 225.
PATEL, K.V. & SCHREY, M.P. (1990). Activation of inositol phos-
pholipid signalling and Ca2' efflux in human breast cancer cells
by bombesin. Cancer Res., 50, 235.
ROZENGURT, E. & SINNETT-SMITH, J. (1980). Bombesin stimulation
of DNA synthesis and cell division in cultures of Swiss 3T3 cells.
Proc. Natl Acad. Sci., 80, 2936.
SHAW, C., THIM, L. & CONLON, J.M. (1987). Primary structure and
tissue distribution of guinea pig gastrin-releasing peptide. J.
Neurochem., 49, 1348.
SORENSON, G.D., BLOOM, S.R., GHATEI, M.A., DEL PRETE, S.A.,
CATE, C.C. & PETTENGILL, O.S. (1982). Bombesin production by
human cell carcinoma of the lung. Regul. Pept., 4, 59.
WEBER, C.J., O'DORISIO, T.M., MCDONALD, T.J., HOWE, B., KOS-
CHITZKY, T. & MERRIAM, L. (1989). Gastrin-releasing peptide-,
calcitonin gene-related peptide-, and calcitonin-like immunoreac-
tivity in human breast cyst fluid and gastrin-releasing peptide-like
immunoreactivity in human breast carcinoma cell lines. Surgery,
106, 1134.
WILLEY, J.C., LECHNER, J.F. & HARRIS, C.C. (1984). Bombesin and
the C-terminal tetradecapeptide of gastrin-releasing-peptide are
growth factors for normal human epithelial cells. Exp. Cell Res.,
153, 1245.